Erratum: Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, Guillaume T, Vigouroux S, El-Cheikh J, Delaunay J, Le Gouill S, Moreau P, Labopin M and Chevallier P. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. Cancer. doi: 10.1002/cncr.29087
- PMID: 25855818
- DOI: 10.1002/cncr.29117
Erratum: Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, Guillaume T, Vigouroux S, El-Cheikh J, Delaunay J, Le Gouill S, Moreau P, Labopin M and Chevallier P. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. Cancer. doi: 10.1002/cncr.29087
Abstract
In Table 1, the numbers for NHL should be 20(25%). In the legend for Figure 1, part (B) should read chronic GVHD is shown. The authors regret these errors.
Erratum for
-
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.Cancer. 2015 Feb 15;121(4):562-9. doi: 10.1002/cncr.29087. Epub 2014 Oct 3. Cancer. 2015. PMID: 25283774 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources